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Abstract
Background: Effective highly active antiretroviral therapy (HAART) reduces human immunodeficiency virus (HIV) 
replication, restores CD4+ T lymphocyte counts and greatly reduces the incidence of opportunistic infections. While 
this demonstrates improved generalized immune function, rapid rebound to pre-treatment viral replication levels 
following treatment interruption indicates little improvement in immune control of HIV replication. The extent to 
which HAART can normalize HIV-specific CD8+ T cell function over time in individuals with chronic infection remains an 
important unresolved issue. In this study, we evaluated the magnitude, general specificity and character of HIV specific 
CD8+ T cell responses at four time points across 2-9 years in 2 groups of chronically infected individuals separated on 
the basis of either effective antiretroviral suppression or ongoing replication of HIV.
Methods: Peripheral blood mononuclear cells (PBMC) were stimulated with overlapping 15mer peptides spanning HIV 
Gag, Pol, Env and Nef proteins. Cells producing interferon-γ (IFN-γ) or interleukin-2 (IL-2) were enumerated by ELISPOT 
and phenotyped by flow cytometry.
Results and Conclusions: The magnitude of the HIV-specific CD8+ T cell response ranged from < .01 to approximately 
1.0% of PBMC and was significantly greater in the group with detectable viral replication. Stronger responses reflected 
higher numbers of CD8+CD45RA- effector memory cells producing IFN-γ, but not IL-2. Magnitude, general specificity 
and character of the HIV-specific CD8+ T cell response changed little over the study period. While antiretroviral 
suppression of HIV in chronic infection reduces HIV-specific CD8+ T cell response magnitude in the short term, it had no 
significant effect on response character over periods up to 9 years.
Background
Human immunodeficiency virus (HIV) infection progres-
sively impairs immune function, including that of the
HIV-specific CD8+ T cells that partially control HIV rep-
lication. This impairment manifests in phenotypic and
functional changes affecting key CD8+ T cell properties
such as proliferation, differentiation, cytokine production
profile, signal transduction, and survival [1-8]. Compared
to cytomegalovirus (CMV)-specific CD8+ T cells, HIV-
specific CD8+ T cells are highly skewed towards effector
memory (Tem) status, suggesting reduced differentiation
into CD45RA+ terminal effectors (Ttd) [9]. In addition,
limited HIV-specific CD8+ T cell proliferation suggests
defective generation and/or maintenance of central mem-
ory T cells (Tcm) [10]. Understanding the fate of these
subset abnormalities in HIV-infected individuals on
highly active antiretroviral therapy (HAART) is impor-
tant for defining the need for complementary treatment
and for gauging practical limits to immune recovery.
When effective, HAART increases CD4+ T lymphocyte
counts, reduces opportunistic infections and according to
early studies, normalizes immune responses [11,12].
However, more specific analyses have recently raised
doubt as to whether HIV-specific CD4+ and CD8+ T cell
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responses recover characteristics normally associated
with effective control of intracellular pathogens [13-18].
Early control of HIV replication may be required to pre-
serve HIV-specific CD4+ T cells and fully functional HIV-
specific CD8+ T cells appear peculiar to those long term
non progressors (LTNP) who maintain low HIV replica-
tion levels without treatment [19]. Thus, a more pessi-
mistic view is that the level to which HIV-specific T cell
responses deteriorate prior to treatment represents an
intractable deficit, insensitive to HAART-related immune
recovery. This issue remains controversial as two recent
studies reached diametrically opposite conclusions of
clear HAART-related improvement versus no change
[20,21]. These conflicting views could reflect different
lenses, a broad range of pre-HAART deterioration in the
groups studied and inherent human variation in thresh-
olds beyond which the possibility or rate of recovery less-
ens.
In this study, we investigated evolution of the magni-
tude, specificity and memory subset distribution of HIV-
specific CD8+ T cell responses over a 2 to 9 year period in
two groups: one with continuous suppression of HIV rep-
lication on HAART; and another with continuously
detectable HIV replication. We reasoned that contrasting
trajectories of the 2 groups would highlight any impact
HAART was having towards reversal or prevention of
HIV-specific CD8+ T cell abnormalities and help resolve
this critical issue.
Methods
Subjects
Study participants recruited through the St. John's Gen-
eral Hospital HIV Clinic, St. John's, Newfoundland, Can-
ada were selected on the basis of ≥ 24 sequential months
of either complete suppression of HIV replication below
levels detectable by plasma virus load testing (< 2.6 or <
1.7 log10 copies HIV RNA/ml plasma by Roche ™Amplicor
standard or ultrasensitive testing respectively) or ≥ 24
sequential months of detectable plasma virus loads. Sub-
jects were grouped accordingly and at least 4 sequential
PBMC samples, over a period as stipulated above, were
selected for analysis. Other relevant immunological and
virological characteristics of the study subjects were
obtained from patient charts and noted accordingly in
results. All participants provided informed consent for
whole blood donation, immunological studies and
researcher access to medical laboratory records. The
Memorial University Faculty of Medicine Human Investi-
gation Committee gave ethical approval for this study.
Peripheral blood mononuclear cell (PBMC) isolation
Acid-citrate-dextrose treated whole blood obtained by
forearm venipuncture at regular intervals concurrent
with medically scheduled bloodwork was diluted 1:2 with
phosphate buffered saline (PBS) and PBMC isolated by
Ficoll-Hypaque (GE Healthcare Bio-Science) density gra-
dient centrifugation. Samples were crypopreserved in
lymphocyte medium consisting of RPMI 1640 with 10%
fetal bovine serum (FBS), 100 IU/ml penicillin, 100 μg/ml
streptomycin, 2 mM L-glutamine, 10 mM HEPES buffer
solution and 2 × 10-5 M 2-mercaptoethanol (all from
Invitrogen) with FBS increased to 20% and supplemented
with 10% dimethylsulfoxide (Sigma).
ELISPOT Assays
Individual PBMC samples from 6 non-infected controls
and series of 4 PBMC samples from 30 HIV-infected indi-
viduals in the 2 groups were stimulated with pools of
overlapping 15mer peptide sets spanning HIV clade B
Gag, Pol, Env and Nef (National Institutes of Health AIDS
Reference Reagent Repository). Individual peptides were
dissolved at 10 mg/ml in DMSO and then pooled in sets
of 49 (Nef), 123 (Gag), 125 (Pol1), 123 (Pol2), 128 (Env1),
and 83 (Env2) in unsupplemented RPMI at a final con-
centration of 1.0 μg/ml of each peptide. Samples were
thawed and cultured overnight before counting to ensure
accurate numbers of viable cells were used. For inter-
feron-γ (IFN-γ) assays, microtitre plates (Multiscreen;
Millipore) were coated overnight at 4°C with 100 μl of 7.5
μg/ml anti-IFN-γ monoclonal antibody (mAb) 1-D1K
(Mabtech) and then washed 3 times with PBS. For inter-
leukin-2 (IL-2) assays, plates were coated overnight at 4°C
with 100 μl of 15 μg/ml anti-IL-2 mAb IL-2-/249
(Mabtech) and then washed 3 times with PBS. Cells were
added at 4.0 or 1.0 × 105/well in 100 μl medium in single
or dual replicates for IL-2 and IFN-γ detection respec-
tively. Peptides (20 μl/pool) were added to a final concen-
tration of 0.1 μg/ml with the volume in each well adjusted
to 200 μl with medium. After overnight (16 hr) incuba-
tion, the plates were washed 6 times as above and 100 μl
of 1 μg/ml biotinylated 7-B6-1 or IL-2-II (Mabtech)
added for 2 h. Plates were then washed 6 times and 100
μl/well of a 1/1000 dilution of streptavidin-alkaline phos-
phatase (AP) (Mabtech) was added for 1 h. Plates were
again washed 6 times and 100 μl/well of chromogenic AP
susbstrate (BioRad) was added. After 30 min, plates were
washed with tap water to stop reactions and then air-
dried. Spots were counted with an Immunoscan reader
(Celluar Technology Limited) and results reported as
IFN-γ spot forming cells (sfc)/106 PBMC (when ≥ 50) or
IL-2 sfc/106 PBMC (when ≥ 0) after subtraction of back-
ground (sfc/106 PBMC cultured overnight in medium
alone).
Flow cytometry
When sufficient cells were available, 1 × 106 PBMC were
incubated overnight with each individual peptide pool or
in medium alone as negative control under the same con-Pohling et al. BMC Infectious Diseases 2010, 10:129
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ditions as ELISPOT except for addition of 10 μg/ml
brefeldin A (Sigma) after 1 h of incubation. If ELISPOT
results indicated ≥ 500 sfc/106 PBMC, the corresponding
samples and controls were processed for flow cytometry.
C e l l s  w e r e  w a s h e d  w i t h  P B S  p l u s  1 %  F C S  a n d  5  m M
EDTA, then surface stained with anti-CD8-PerCP (clone
RPA-T8, Biolegend) and anti-CD45RA-PE (clone JS-83,
eBioScience). After washing, cells were fixed, permeabi-
lized (Dako intrastain), and stained with anti-IFN-γ-APC
(clone 4S-B3, eBioScience). At least 200,000 events were
acquired on a FacsCalibur flow cytometer (Becton Dick-
enson) and CD8+ cells gated and analyzed for IFN-γ and
CD45RA expression with Cellquest Pro software (Becton
Dickenson).
Statistical analysis
Statistical analysis was carried out with GraphPad Prism
4.03 Software. Normality of data distribution was
assessed by the Kolmogrov-Smirnov test. When data was
normally distributed, means were presented for compari-
son. If data did not fit a normal distribution, medians
were presented for comparison. Repeated measures
ANOVA was used to compare the frequency of HIV-spe-
cific CD8+ T cells producing IFN-γ or IL-2 between and
within groups at different time points and to compare
between groups the percentage of CD45RA+ HIV-specific
CD8+ T cells producing IFN-γ. Paired Student's t test was
used to compare initial and final CD4+ T lymphocyte
counts and initial and final percentages of CD45RA+
HIV-specific CD8+  T cells producing IFN-γ within
groups. Probability values < 0.05 were considered signifi-
cant.
Results
Subjects' characteristics
General characteristics of the two HIV-infected groups
prior to and over the course of the study are reported in
table 1 (undetectable viral replication) and table 2
(detectable viral replication). All subjects were chroni-
cally infected for a documented duration of from at least
5 to > 15 years. Most individuals in both groups had
endured relatively high levels of HIV replication and had
progressed to advanced HIV infection at some point as
illustrated by zenith viral loads and CD4 nadirs < 200/μL
peripheral blood. Those in the uncontrolled replication
group had plasma virus loads throughout the study
course that were substantially lower than their zenith,
suggesting partial efficacy of their antiretroviral therapy
as the recorded zenith was not associated with acute
infection. Three individuals (187, 195 and 209) in the
uncontrolled infection group had never received antiret-
roviral therapy up to and through the course of this study,
while all others in both groups had received HAART in
the form of triple therapy with drugs of at least 2 classes.
The documented duration of undetectable plasma virus
load in the controlled infection group ranged from 3 to 84
months preceding this study.
Evolution of the magnitude and specificity of CD8+ anti-HIV 
T cell responses
ELISPOT testing of control PBMC (Figure 1) and 4
sequential PBMC samples from 15 individuals with per-
sistently undetectable virus load (Figure 2) and 15 indi-
viduals with persistently detectable virus load (Figure 3)
was carried out as shown. The cumulative number of
INF-γ sfc/106 PBMC stimulated by the peptide pools rep-
resenting HIV Gag, Pol, Env and Nef was taken as overall
magnitude of the CD8+ anti-HIV T cell response. Cells
producing IFN-γ in response to the HIV peptides were
almost exclusively CD8+ as no increase over control val-
ues in the percentage of non-CD8+ T cells producing
IFN-γ was detectable by flow cytometry in any of the
samples tested (data not shown). The fractional contribu-
tion of each individual HIV protein to overall magnitude
indicated general specificity. The six uninfected controls
had cumulative responses from 0-61 (median = 23) IFN-γ
and 0-38 (median = 4) IL-2 sfc/106 PBMC in response to
the HIV peptide pools, demonstrating the specificity and
low background of the peptide ELISPOT assay. In the
undetectable virus load group, overall magnitude of the
CD8+ anti-HIV T cell response ranged from 67 sfc/106
PBMC to 5166 sfc/106 PBMC (Figure 4). Median overall
CD8+ anti-HIV T cell response magnitude in this group
remained consistent over the course of study, beginning
at 874 and finishing at 895 sfc/106 PBMC, indicating no
long-term decay in the magnitude of the CD8+ anti-HIV
T cell response, despite apparently effective antiretroviral
therapy. Mean CD4+ T cell count rose from 511 to 729/μl
peripheral blood over the same time period (P = .002). If
> 50% of the total INF-γ sfc were specific for 1 of the 4
major HIV proteins, we considered the response against
this protein immunodominant. At the first study point
Gag was the dominant CD8+ T cell antigen for 6, Pol for 1,
Nef for 2 and Env for 0 individuals in the undetectable
virus group. This pattern persisted through the fourth
study point with Gag immunodominant for 6, Pol for 2,
Nef for 2 and Env for 0 individuals (Figure 5). In the
absence of detectable HIV replication, several dramatic
shifts in general antigenic dominance still occurred, from
Gag to Pol (subject 50) and Pol to Gag (subject 128) (Fig-
ure 5). These cases of shifting immunodominance or
epitope spreading together with persistently high HIV-
specific CD8+ T cell responses suggest immune stimula-
tion by ongoing viral replication at levels undetectable by
clinical virus load testing.
In the detectable virus load group, overall CD8+ anti-
HIV T cell response magnitude ranged from 608 to 9856Pohling et al. BMC Infectious Diseases 2010, 10:129
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sfc/106  PBMC and increased (non-significant) from a
median of 1587 to a median of 1889 sfc/106 PBMC over
the course of the study (Figure 4). Median CD8+ anti-HIV
T cell response magnitude was significantly higher in the
detectable virus load group than in controlled virus repli-
cation group (P < .0001). The mean CD4+ T cell count
was unchanged at 553 versus 524/μl peripheral blood at
initial and final time points. Although these subjects had
detectable virus replication throughout the study, all but
three (187, 195 and 209) received partially suppressive
antiretroviral therapy, either persistently or intermit-
tently. At the first study point, Gag was the dominant
CD8+ T cell antigen for 2, Pol for 1, Nef for 1 and Env for
1 individual in the detectable virus load group. By the
fourth study point, Gag was immunodominant for 3, Pol
for 3, Nef for 0 and Env for 0 individuals (Figure 6).
Evolution of memory status of CD8+ anti-HIV T cell 
responses
Central memory (Tcm) HIV-specific CD8+ T cells are
rare in progressive HIV infection and difficult to accu-
rately enumerate by flow cytometry [10]. Therefore, we
measured IL-2 producing cells by ELISPOT to estimate
HIV-specific CD8+ Tcm numbers (Figures 1, 2, 3). As
expected, these were much less frequent than IFN-γ pro-
ducing HIV-specific CD8+ T cells. Although at lower
absolute levels, response distribution across the 4 HIV
antigens tested and overall expansion/contraction of the
HIV-specific CD8+ T cell IL-2 response generally mir-
rored that of the HIV-specific CD8+  T cell IFN-γ
response. For 12 individuals with the most prominent IL-
2 sfc responses, individual peptides stimulating IL-2 were
identified using peptide matrices from the appropriate
peptide set. Optimal 9mers previously identified within
the 15mers http://www.hiv.lanl.gov/content/immunol-
ogy/ctl_search were then shown to stimulate IL-2 pro-
duction, confirming that CD8+ class I-restricted T cells
were responsible for the IL-2 production. In the unde-
tectable virus load group, the magnitude of the CD8+
anti-HIV T cell IL-2 response ranged from 0 to 508 sfc/
106 PBMC (Figure 7). Over the course of the study, the
median overall CD8+ anti-HIV T cell IL-2 response mag-
nitude remained similar at 56 and 50 sfc/106 PBMC at
Table 1: General characteristics and changes for subjects with undetectable HIV replication
ID Duration 
of infection
aVL zenith bCD4 
nadir
cDuration 
of suppression
dCD4i CD4f eMonths 
study course
fCD8+ 
IFNγ+ CD45RA+i
CD8+ IFNγ+ CD45RA+f
27 >15 yrs 5.13 308 21 months 702 1364 90 13% 26%
30 >15 yrs 4.53 314 84 months 630 1089 28 ND ND
50 >15 yrs 5.45 18 7 months 220 627 108 52% 50%
62 >15 yrs 4.61 154 32 months 738 756 28 10% 15%
90 >15 yrs 6.22 73 24 months 280 352 96 79% 84%
109 >15 yrs 3.66 145 72 months 740 665 24 22% 16%
128 >12 yrs 4.53 364 3 months 570 912 66 44% 52%
134 >12 yrs 5.01 96 72 months 850 1020 24 ND ND
143 >10 yrs 4.77 400 24 months 400 682 60 ND 22%
149 >9 yrs 5.67 9 36 months 338 264 24 ND ND
155 >9 yrs 5.10 210 3 months 368 408 54 10% 10%
174 >7 yrs 5.53 380 12 months 494 768 30 ND ND
176 >7 yrs <2.6 245 12 months 361 750 36 ND ND
193 >6 yrs <2.6 40 12 months 405 324 24 23% 13%
200 >5 yrs >5.88 192 3 months 567 957 24 ND ND
aThe highest recorded virus load (VL) for each subject in log10 copies HIV RNA/mL plasma.
bThe lowest recorded peripheral blood CD4+ T lymphocyte count for each subject.
cThe length of time before analysis of HIV-specific CD8+ T cell responses for which each subject experienced suppression of viremia below 
detectable levels.
dThe number of CD4+ T lymphocytes/μL peripheral blood for each subject at beginning (CD4i) and end (CD4f) of period over which HIV-specific 
CD8+ T cell responses were assessed.
eTotal time period over which four assessments of HIV-specific CD8+ T cell responses occurred.
fPercentage of HIV-specific CD8+ T cells producing INF-γ that expressed CD45RA at beginning (i) and end (f) of period over which HIV-specific 
CD8+ T cell responses were assessed.Pohling et al. BMC Infectious Diseases 2010, 10:129
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time points 1 and 4 respectively. In the detectable virus
load group, the magnitude of the CD8+ anti-HIV T cell
IL-2 response ranged from 0 to 940 sfc/106 PBMC and
remained stable at a median of 43 and 55 sfc/106 PBMC at
time points 1 and 4 respectively (Figure 7). There was no
significant difference in the magnitude of CD8+ HIV-spe-
cific IL-2 sfc/106 PBMC between groups and no signifi-
cant changes in the magnitude of the response in either
group over the course of the study. Viral replication
reduced the fraction of HIV-specific CD8+ Tcm with no
impact on absolute number. Long term suppression of
HIV replication had little impact on either the fraction or
absolute number of CD8+ HIV-specific IL-2 sfc.
Since the contribution of CD45RA+ naïve T cells to in
vitro HIV-specific T cell responses is minimal, terminally
differentiated HIV-specific CD8+ effector cells can be dis-
tinguished by co-expression of intracellular IFN-γ and
surface CD45RA following stimulation with HIV pep-
tides. When cells were available and ELISPOT results
indicated enough IFN-γ producing cells for phenotypic
analysis of HIV-specific CD8+ T cells by flow cytometry,
we estimated the fraction of Ttd through CD45RA
expression on HIV-specific CD8+ T cells producing IFN-γ
(Figure 8). In the undetectable virus load group, the
CD45RA+  percentage of the CD8+  anti-HIV T cell
response ranged from 13% to 84% (Table 1), but did not
increase from a mean of 32% over the course of the study.
In the detectable virus load group, the CD45RA+ percent-
age of the CD8+ anti-HIV T cell response ranged from 6%
to 37% and fell from a mean of 23% to 17% over the
course of the study. This decrease was not statistically sig-
nificant. We observed a generally low percentage of CD8+
anti-HIV T cells expressing CD45RA+ throughout both
groups of subjects, corroborating previous reports on
impaired terminal differentiation of HIV-specific CD8+ T
cells [9,14].
Discussion and Conclusions
The unusually low fractions of HIV-specific CD8+ Tdt
and Tcm detected in progressive infection suggest
impaired differentiation may be a key factor in HIV-spe-
cific CD8+ T cell dysfunction and progression to acquired
immune deficiency syndrome (AIDS) [9,10,14]. Since
CD8+ T cells themselves are rarely HIV-infected, their
impairment relates indirectly to HIV replication. Thus,
Table 2: General characteristics and changes for subjects with detectable HIV replication
ID Duration 
of infection
aVL zenith bCD4 nadir cVL study 
course
dCD4i CD4f eMonths 
study course
fCD8+ IFNγ+ 
CD45RA+i
CD8+ IFNγ+ CD45RA+f
11 >15 yrs >5.88 63 4.58 308 335 60 15% 16%
17 >15 yrs 4.48 296 4.12 518 490 30 ND ND
35 >15 yrs 4.77 176 3.37 660 736 48 35% 12%
39 >15 yrs 5.64 24 2.70 754 961 30 6% 14%
51 >15 yrs 5.61 40 3.29 390 297 36 33% 25%
57 >15 yrs 5.48 176 4.25 420 506 36 14% 8%
77 >15 yrs 5.00 207 3.80 692 288 24 ND ND
78 >15 yrs >5.88 32 4.53 110 184 36 24% 23%
85 >14 yrs 4.60 307 2.65 684 663 66 11% 11%
98 >13 yrs 5.73 69 3.79 484 435 48 ND ND
116 >12 yrs 5.56 44 3.22 319 378 48 23% 23%
125 >12 yrs 5.06 59 4.52 496 209 42 31% ND
187 >7 yrs 3.93 1064 2.89 1127 1419 36 37% ND
195 >5 yrs 4.93 462 4.54 518 462 24 27% 25%
209 >5 yrs 4.97 500 4.72 812 500 24 ND ND
aThe highest recorded virus load (VL) for each subject in log10 copies HIV RNA/mL plasma.
bThe lowest recorded peripheral blood CD4+ T lymphocyte count for each subject.
cVirus load (log10 copies HIV RNA/mL plasma) averaged over the 4 time points for each subject.
dThe number of CD4+ T lymphocytes/μL peripheral blood for each subject at beginning (CD4i) and end (CD4f) of period over which HIV-specific 
CD8+ T cell responses were assessed.
eTotal time period over which four assessments of HIV-specific CD8+ T cell responses occurred.
fPercentage of HIV-specific CD8+ T cells producing INF-γ that expressed CD45RA at beginning (i) and end (f) of period over which HIV-specific 
CD8+ T cell responses were assessed.Pohling et al. BMC Infectious Diseases 2010, 10:129
http://www.biomedcentral.com/1471-2334/10/129
Page 6 of 10
whether HAART normalizes HIV-specific CD8+ T cell
differentiation in chronic infection remains unknown. In
this study, we used overlapping peptides encompassing
all of HIV Gag, Pol, Env and Nef to broadly examine HIV-
specific CD8+ T cell responses and address the impact
successful antiretroviral suppression of HIV replication
had on these responses. We compared evolution of the
magnitude, specificity and character of HIV-specific
CD8+ T cell responses in two groups of individuals, both
chronically infected with HIV, but distinguished by con-
tinuously detectable versus undetectable HIV replication
over study periods from 2-9 years.
We found that the HIV-specific CD8+CD45RA+ popu-
lation, which includes Tdt, were relatively scarce through-
out the detectable virus replication group and most of the
undetectable virus replication group. While such paucity
was previously described in studies focused on individual
epitopes, the use of genome wide peptide pools herein
clarifies its broader relevance to the HIV-specific CD8+ T
cell response [9,14]. The percentage of CD45RA+ effec-
tors, together with the absolute number of HIV-specific
CD8+ T cells remained relatively constant in both groups,
consistent with establishment of stable ratios under
Figure 1 Detection of HIV-specific IFN-γ and IL-2 spot forming 
cells (sfc) in uninfected controls. Individual PBMC samples from four 
(C1, C2, C3 and C4) of six uninfected individuals tested by ELISPOT with 
medium alone (Neg), PHA and overlapping peptide pools from HIV 
Gag, Pol, Env and Nef for IFN-γ (duplicate) and IL-2 (single replicate) sfc 
are shown.
Figure 2 Detection of HIV-specific IFN-γ and IL-2 spot forming 
cells in HIV-infected individuals with continuous suppression of 
viral replication. Four PBMC samples taken on dates shown on top of 
the figure from a representative HIV-infected individual with continu-
ous suppression of viral replication were tested as described in figure 1.
Figure 3 Detection of HIV-specific IFN-γ and IL-2 spot forming 
cells in HIV-infected individuals with continuously detectable HIV 
replication. Four PBMC samples taken from a representative HIV-in-
fected individual with continuously detectable HIV replication on 
dates shown on top of the figure together with concurrent log10 cop-
ies HIV RNA/ml plasma were tested as described in figure 1.
Figure 4 Frequency of HIV-specific CD8+ T cells producing IFN-γ 
in chronically infected individuals with ongoing HIV replication 
either detectable () or suppressed below detectable levels (). 
The total number of HIV-specific CD8+ T cells producing IFN-γ/106 
PBMC in response to Gag, Pol, Env and Nef peptide pools is shown for 
each individual at 4 serial time points with horizontal line through the 
group representing the median frequency.Pohling et al. BMC Infectious Diseases 2010, 10:129
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chronic conditions of either antiretroviral suppression or
HIV replication. While the overall similar character of
HIV-specific CD8+ T cell responses in both groups also
supports the notion of intransigence to antiretroviral
therapy, we did not compare the same individuals before
and after introduction of successful antiretroviral ther-
apy. Therefore, improvements in the character of HIV-
specific CD8+ T cell responses occurring early after onset
of antiretroviral therapy would not have been detected in
this study.
Although these responses would likely not be detect-
able by flow cytometry with individual peptides, we
detected CD8+ HIV-specific IL-2 responses in nearly half
of the chronically infected individuals we tested by
ELISPOT with peptide sets covering the entire HIV
genome. The absolute and relative frequencies of HIV-
specific CD8+ T cells producing IL-2 were, nonetheless,
very low in both groups, confirming that few, or in some
cases, none of the HIV-specific CD8+CD45RA- T cells
were Tcm. The low numbers of HIV-specific IL-2 sfc
indicate that only a very small fraction of the HIV-spe-
cific CD8+CD45RA- IFN-γ producing T cells are Tcm.
Therefore, prolonged or repeated expansion of HIV-spe-
cific effector cells skews the HIV-specific CD8+ T cell
population towards a predominant effector memory
(Tem) phenotype and this skewing is not reversed by
long-term suppression of HIV replication.
Identifying HIV-specific CD8+  Tcm other than by
expression of surface markers such as CCR7 could con-
ceivably underestimate Tcm numbers, but proliferative
function as indicated by IL-2 production may be a more
meaningful discriminator of HIV-specific CD8+  Tcm.
The lower fraction of HIV-specific CD8+ Tcm thus identi-
fied in the group with detectable HIV replication actually
reflected higher absolute Tem numbers in this group, not
fewer Tcm. Absolute Tcm numbers changed little over
time in either group, implying a rough equilibrium of
HIV-specific T cell subset distribution under relatively
stable conditions of antiretroviral suppression or HIV
replication. Thus, it appears that in stable settings of
Figure 5 Fractional specificity of the overall HIV-specific CD8+ T cell response. The fraction of the overall HIV specific CD8+ T cell response attrib-
uted to each of the 4 major HIV proteins is shown by differential bar graph shading for individuals in the undetectable viral replication groups at each 
of 4 sequential time points tested.Pohling et al. BMC Infectious Diseases 2010, 10:129
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either viral replication or antiretroviral suppression, indi-
viduals reach a steady-state HIV-specific CD8+ T cell
response, analogous and related to virus load set-point
[22]. This equilibrium would shift with acute expansion
of Tem upon de novo viral replication or contraction of
Tem with introduction of effective HAART. In our study,
where initial samples were drawn at least 3 months after
establishment of viral suppression or viral replication, the
absolute magnitude, general specificity and subset distri-
bution of the CD8+ anti-HIV T cell response remained
remarkably constant. This suggests an enormous reserve
of CD8+ HIV-specific effector cells, although previous or
partially effective treatment probably also played a role in
the durability of responses in our study group. In progres-
sive infection, HIV-specific CD8+ T cell activation, subset
distribution and elimination maintains a set point that
slowly decays towards true numerical deficits only in
advanced infection. Set point maintenance in treated
non-progressing subjects with undetectable viral loads
indicates occult viral replication sufficient for continuous
recruitment of relatively short-lived CD8+ HIV-specific
Tem or some residual conditioning of the immune system
that perpetuates aberrant differentiation and subset dis-
tribution of HIV-specific CD8+ T cells. Such low level
replication, as was recently confirmed in both elite con-
trollers and treated individuals with clinically undetect-
able virus loads, may be an important component of
immune deficits that persist in chronic, treated HIV
infection [19,23].
In humans, there are clear associations between initial
suppression of viral replication and emergence of HIV-
specific CD8+ T cells as well as between advanced disease
progression and decline of HIV-specific CD8+ T cells [24-
26]. In macaques, depletion of CD8+ T cells in macaque
models of HIV infection directly demonstrated the role
that CD8+ T cells play in lowering virus load in acute
infection and delaying disease progression in chronic
infection [27]. However, the coexistence of strong anti-
HIV CD8+ T cell responses with substantial levels of HIV
replication that we and others have observed raises ques-
Figure 6 Fractional specificity of the overall HIV-specific CD8+ T cell response. The fraction of the overall HIV specific CD8+ T cell response attrib-
uted to each of the 4 major HIV proteins is shown by differential bar graph shading for individuals in the detectable viral replication groups at each of 
4 sequential time points tested.Pohling et al. BMC Infectious Diseases 2010, 10:129
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tions as to the long term contribution of these natural
responses [28]. Some data indicate that clonal restriction
of the HIV-specific CD8+ T cell response is the earliest
predictor of rapid disease progression, suggesting that the
initial dynamics of CD8+ T cell-mediated suppression of
viral replication versus viral dissemination, diversification
and immune destruction play a major role in determining
the steady-state parameters of chronic infection [17,29].
Our data indicate that antiretroviral treatment in chronic
HIV infection shifts the steady state towards slower decay
and lower HIV-specific CD8+ Tem frequencies without
affecting the overall character of the HIV-specific CD8+ T
cell response. Without supplementary immunological
conditioning to enhance the efficacy of HIV-specific
immunity, the system will return to its original trajectory
upon treatment failure or withdrawal.
In summary, we found no evidence that effective anti-
retroviral therapy influences any feature other than mag-
nitude of HIV-specific CD8+  T cell responses. Low
frequencies of CD8+ HIV-specific Tcm and low fractions
of CD45RA+ Tdt persisted over prolonged periods of
effective HAART, suggesting that abnormal characteris-
tics of the HIV-specific CD8+ T cell response imprinted
following acute infection endure immune restoration
associated with HAART. However, none of the subjects in
our study received antiretroviral therapy during acute
infection, which may be more likely to influence HIV-
specific CD8+ T cell differentiation and subset distribu-
tion than treatment during chronic infection. Novel strat-
egies addressing HIV-specific CD8+  T cell response
character will be required to achieve true immune resto-
ration in chronic HIV infection.
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